Is CyberArk The Next Big Cybersecurity Stock?
CyberArk Software (NASDAQ: CYBR) recently reported phenomenal quarter numbers, passing…
Sell
43
GSK Quote, Financials, Valuation and Earnings
Last price:
$40.39
Seasonality move
:
4.92%
Day range:
$39.85 - $40.47
52-week range:
$31.72 - $45.93
Dividend yield:
3.86%
P/E ratio:
25.42x
P/S ratio:
2.07x
P/B ratio:
4.78x
Volume:
4.2M
Avg. volume:
5.6M
1-year change:
-4.6%
Market cap:
$82B
Revenue:
$40.1B
EPS (TTM):
$1.58
Analysts' Opinion
-
Consensus RatingGSK PLC has received a consensus rating of Hold. The company's average rating is a Hold based on 2 Buy ratings, 3 Hold ratings, and 1 Sell rating.
-
Price Target UpsideAccording to analysts' consensus price target of $43.42, GSK PLC has an estimated upside of 7.88% from its current price of $40.25.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $35.50 representing 100% downside risk from its current price of $40.25.
Fair Value
-
According to the consensus of 6 analysts, GSK PLC has 7.88% upside to fair value with a price target of $43.42 per share.
GSK vs. S&P 500
-
Over the past 5 trading days, GSK PLC has underperformed the S&P 500 by -1.51% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
GSK PLC does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
GSK PLC has grown year-over-year revenues for 7 quarters straight. In the most recent quarter GSK PLC reported revenues of $10.4B.
Earnings Growth
-
GSK PLC has grown year-over-year earnings for 1 quarter straight. In the most recent quarter GSK PLC reported earnings per share of $0.26.
Enterprise value:
96.5B
EV / Invested capital:
2.66x
Price / LTM sales:
2.07x
EV / EBIT:
18.47x
EV / Revenue:
2.41x
PEG ratio (5yr expected):
--
EV / Free cash flow:
21.15x
Price / Operating cash flow:
18.22x
Enterprise value / EBITDA:
11.37x
Gross Profit (TTM):
$28.5B
Return On Assets:
4.35%
Net Income Margin (TTM):
8.13%
Return On Equity:
19.22%
Return On Invested Capital:
8.51%
Operating Margin:
27.31%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $36.2B | $37.7B | $40.1B | $10B | $10.4B | |
| Gross Profit | $24.4B | $27.1B | $28.5B | $7B | $7.1B | |
| Operating Income | $8.4B | $9.1B | $7.1B | $1.5B | $2.8B | |
| EBITDA | $10.9B | $11.3B | $8.5B | $1.4B | $1.4B | |
| Diluted EPS | $8.69 | $2.99 | $1.58 | $0.21 | $0.26 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $27.6B | $25.2B | $25.1B | $23.8B | $21.3B | |
| Total Assets | $109.6B | $106.8B | $72.8B | $75.2B | $74.6B | |
| Current Liabilities | $30.2B | $31.9B | $27.6B | $26.8B | $27.2B | |
| Total Liabilities | $81.3B | $78B | $60.6B | $58.9B | $58.2B | |
| Total Equity | $28.4B | $28.8B | $12.2B | $16.3B | $16.4B | |
| Total Debt | $35.5B | $31.3B | $24.2B | $21.4B | $19.9B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $9.2B | $8.4B | $8.4B | $3.9B | $2.9B | |
| Cash From Investing | -$10.9B | -$2B | -$1.6B | $374.3M | -$1.4B | |
| Cash From Financing | $1B | -$7B | -$6B | -$4.4B | -$986M | |
| Free Cash Flow | $6.4B | $5.5B | $4.6B | $3B | $1.5B | |
GSK
Sector
Market Cap
$82B
$37.4M
Price % of 52-Week High
87.64%
45.61%
Dividend Yield
3.86%
0%
Shareholder Yield
6.16%
-0.75%
1-Year Price Total Return
-4.6%
-38.36%
Beta (5-Year)
0.601
0.774
Dividend yield:
3.86%
Annualized payout:
$1.56
Payout ratio:
95.78%
Growth streak:
1 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$39.44
200-day SMA
Buy
Level
$38.19
Bollinger Bands (100)
Buy
Level
33.67 - 37.57
Chaikin Money Flow
Buy
Level
376.7M
20-day SMA
Buy
Level
$38.13
Relative Strength Index (RSI14)
Buy
Level
67.23
ADX Line
Buy
Level
34.93
Williams %R
Sell
Level
-14.5478
50-day SMA
Buy
Level
$36.00
MACD (12, 26)
Buy
Level
1.06
25-day Aroon Oscillator
Buy
Level
68
On Balance Volume
Neutral
Level
199.7M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (1.5703)
Sell
CA Score
(Annual)
Level (-1.1871)
Buy
Beneish M-Score
(Annual)
Level (-2.8362)
Buy
Momentum Score
Level (4)
Sell
Ohlson Score
Level (0.9115)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (7)
Revenue Forecast
Earnings per Share Forecast
Company Profile
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, antiviral, and vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Stock Forecast FAQ
In the current month, GSK has received 2 Buy ratings 3 Hold ratings, and 1 Sell ratings. The GSK average analyst price target in the past 3 months is $43.42.
-
Where Will GSK PLC Stock Be In 1 Year?
According to analysts, the consensus estimate is that GSK PLC share price will rise to $43.42 per share over the next 12 months.
-
What Do Analysts Say About GSK PLC?
Analysts are divided on their view about GSK PLC share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that GSK PLC is a Sell and believe this share price will drop from its current level to $35.50.
-
What Is GSK PLC's Price Target?
The price target for GSK PLC over the next 1-year time period is forecast to be $43.42 according to 6 Wall Street analysts, 2 of them rate the stock a Buy, 1 rates the stock a Sell, and 3 analysts rate the stock a Hold.
-
Is GSK A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for GSK PLC is a Hold. 3 of 6 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of GSK?
You can purchase shares of GSK PLC via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase GSK PLC shares.
-
What Is The GSK PLC Share Price Today?
GSK PLC was last trading at $40.39 per share. This represents the most recent stock quote for GSK PLC. Yesterday, GSK PLC closed at $40.25 per share.
-
How To Buy GSK PLC Stock Online?
In order to purchase GSK PLC stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is the Market Going to Go Lower?
The last month has been extremely difficult for the stock…
2 Dividend Stocks to Buy in a Recession
While many economists and investors initially expected 2025 to be…
Stock Ideas
Buy
53
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Buy
54
Is NVDA Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 41x
Buy
51
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Alerts
Buy
52
RGC alert for Mar 18
Regencell Bioscience Holdings [RGC] is up 73.51% over the past day.
Buy
63
EXOD alert for Mar 18
Exodus Movement [EXOD] is down 3.96% over the past day.
Sell
45
MNPR alert for Mar 18
Monopar Therapeutics [MNPR] is up 0.93% over the past day.
